Our current data provided a novel insight into anti-VEGF-A therapeutic strategies in terms that aflibercept traps galectin-1, a VEGF-A-independent VEGFR2 ligand associated with the pathogenesis of PDR as well as various retinal disease models. Here, VEGFA is linked to Abnormal retinal morphology.